Actinium Pharmaceuticals (NYSE:ATNM) Shares Down 4.3% – Here’s Why

Actinium Pharmaceuticals, Inc. (NYSE:ATNM)’s share price fell 4.3% during trading on Thursday . The stock traded as low as $1.10 and last traded at $1.11. 288,753 shares traded hands during mid-day trading, an increase of 89% from the average session volume of 152,679 shares. The stock had previously closed at $1.16.

Wall Street Analyst Weigh In

Separately, Stephens reaffirmed an “overweight” rating and issued a $5.00 target price on shares of Actinium Pharmaceuticals in a research report on Tuesday, March 31st. Two research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $4.50.

Actinium Pharmaceuticals Price Performance

The business has a 50 day simple moving average of $1.19 and a 200 day simple moving average of $1.26. The company has a market capitalization of $33.89 million, a price-to-earnings ratio of -0.78 and a beta of -0.06.

Institutional Investors Weigh In On Actinium Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in ATNM. Bank of America Corp DE raised its position in shares of Actinium Pharmaceuticals by 76.6% during the 4th quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after acquiring an additional 34,176 shares in the last quarter. AQR Capital Management LLC raised its position in shares of Actinium Pharmaceuticals by 278.6% during the 1st quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock worth $102,000 after acquiring an additional 46,545 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Actinium Pharmaceuticals during the 2nd quarter worth about $137,000. Qube Research & Technologies Ltd acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter worth about $70,000. Finally, Jane Street Group LLC acquired a new stake in shares of Actinium Pharmaceuticals during the second quarter worth about $306,000. Institutional investors and hedge funds own 27.50% of the company’s stock.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell?killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab?B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab?B, Actinium’s pipeline includes Actimab?A, an anti?CD33 antibody labeled with the radioisotope bismuth?213 for the treatment of relapsed or refractory AML.